That 36.6-pound average, in people who had been diabetic for a mean of just 2.5 years, is a signal that the glucagon receptor component the distinguishing third arm of this GIP/GLP-1/glucagon triple agonist is doing real metabolic work beyond what dual agonism alone achieves
How to Talk to Your Doctor About Starting GLP-1 Therapy Starting a new therapy can be daunting, especially when it comes to managing a chronic condition like diabetes
Their protective functions include reducing paracellular permeability, boosting innate immune responses against pathogens, and consolidating the physical barrier provided by the mucous layer (163)
The role of DPP4i in diabetic HFpEF Unlike GLP-1 RA and SGLT2i, DPP4i, a relatively new class of anti-diabetic drugs, have aroused controversy due to inconsistency about their cardiovascular effects in diabetic HFpEF (Table 4)
The combination of precise dosing and optimized nutrition produces dramatically better outcomes than medication alone
This can vary from person to person